Selective effect of serum on bacterial LPS-induced IL-6 and nitric oxide production in murine peritoneal macrophages

Journal of Endotoxin Research

Volumn 3, Issue 5, 1996, Pages 395-405

  Hirohashi, N ^a,c   Richards, M ^a,d   Morrison, D C ^a,b  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^c KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d RARAF Nevis Labs ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD14 ANTIGEN; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; NITRIC OXIDE;

ANIMAL CELL; ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; MACROPHAGE; MOUSE; NONHUMAN; PERITONEUM CELL; POLYMERASE CHAIN REACTION; SERUM; STAPHYLOCOCCUS AUREUS;

ANIMALIA; BACTERIA (MICROORGANISMS); MURINAE; STAPHYLOCOCCUS AUREUS;

EID: 0029730753     PISSN: 09680519     EISSN: None     Source Type: Journal    
DOI: 10.1177/096805199600300503     Document Type: Article

References (46)

1. Morrison D.C., Ryan J.L. Bacterial endotoxin and host immune responses. Adv Immunol 1987; 28: 293-450.
2. Tobias P.S., Soldau K., Ulevitch R.J. Isolation of a lipopolysaccharide-binding acute phase reactant from rabbit serum. J Exp Med 1986; 164: 777-793.
3. Schumann R.R., Leong S.R., Flaggs G.W. et al. Structure and function of lipopolysaccharide binding protein. Science 1990; 249: 1429-1431.
4. Mathison J.C., Tobias P.S., Wolfsen E., Ulevitch R.J. Plasma lipopolysaccharide (LPS)-binding protein. A key component in macrophage recognition of Gram-negative LPS. J Immunol 1992; 149: 200-206.
5. Gallay P., Carrel S., Glauser M.P. et al. Purification and characterization of murine lipopolysaccharide-binding protein. Infect Immun 1993; 61: 378-383.
6. Martin T.R., Mathison J.C., Tobias P.S. et al. Lipopolysaccharide binding protein enhances the responsiveness of alveolar macrophages to bacterial lipopolysaccharide. J Clin Invest 1992; 90: 2209-2219.
7. Corradin S.B., Manuel J., Gallay P., Heumann D., Ulevitch R.J., Tobias P.S. Enhancement of murine macrophage binding of and response to bacterial lipopolysaccharide (LPS) by LPS-binding protein. J Leukoc Biol 1992; 52: 363-368.
8. Wright S.D., Ramos R.A., Tobias P.S., Ulevitch R.J., Mathison J.C. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 1990; 249: 1431-1433.
9. Haziot A., Tsuberi B-Z., Goyert S.M.. Neutrophil CD14: biochemical properties and role in the secretion of tumor necrosis factor-α in responses to lipopolysaccharide. J Immunol 1993; 150: 5556-5565.
10. Lee J-D., Kato K., Tobias P.S., Kirkland T.N., Ulevitch R.J. Transfection of CD14 into 70Z/3 cells dramatically enhances the sensitivity to complexes of lipopolysaccharide (LPS) and LPS binding protein. J Exp Med 1992; 175: 1697-1705.
11. Frey E.A., Miller D.S., Jahr T.G. et al. Soluble CD14 participates in the response of cells to lipopolysaccharide. J Exp Med 1992; 176: 1665-1671.
12. Wurfel, M.M., Kunitake S.T., Lichenstein H., Kane J.P., Wright S.D. Lipopolysaccharide (LPS)-binding protein is carried on lipoproteins and aas as a cofactor in the neutralization of LPS. J Exp Med 1994; 180: 1025-1035.
13. Lynn W.A., Liu Y., Golenbock D.T. Neither CD14 nor serum is absolutely necessary for activation of mononuclear phagocytes by bacterial lipopolysaccharide. Infect Immun 1993; 61: 4452-4461.
14. 2-terminal amino acid sequence of a T-cell derived lymphokine with growth factor activity for B cell hybridomas. Proc Natl Acad Sci USA 1986; 83: 9679-9683.
15. Wright S.D., Ramos R.A., Patel M., Miller D.S. Septin : a factor in plasma that opsonizes lipopolysaccharide-binding protein particles for recognition by CD14 on phagocytes. J Exp Med 1992; 176: 719-727.
16. Dentener M.A., Bazil V., Eckhardt J.U., Asmuth V., Ceska M., Buurman W.A. Involvement of CD14 in lipopolysaccharide-induced tumor necrosis factor-alpha, IL-6 and IL-8 release by human monocytes and alveolar macrophages. J Immunol 1993; 150: 2885-2891.
17. Gallay P., Jongeneel C.V., Barras C. et al. Short time exposure to lipopolysaccharide is sufficient to activate human monocytes. J Immunol 1993; 150: 5086-5093.
18. Lorsbach R.B., Murphy W.J., Lowenstein C.J., Snyder S.H., Russell S.W. Expression of the nitric oxide synthase gene in mouse macrophages activated for tumor cell killing. J Biol Chem 1993; 268: 1908-1913.
19. Schneemann M, Schoedon G., Hofer S., Blau N., Guerrero L., Shaffner A. Nitric oxide synthase is not a constituent of the antimicrobial armature of human mononuclear phagocytes. J Infect Dis 1993; 167: 1358-1363.
20. Yang Z., Khemiani L.S., Dean D.F., Carter C.D., Slauson D.O., Bochsler P.N. Serum components enhance bacterial lipopolysaccharide-induced tissue factor expression and tumor necrosis factor-alpha secretion by bovine alveolar macrophages in vitro. J Leukoc Biol 1994; 55: 483-488.
21. Wright S.D., Tobias P.S., Ulevitch R.J., Ramos R.A. Lipopolysaccharide (LPS) binding protein opsonizes LPS-bearing particles for recognition by a novel receptor on macrophages. J Exp Med 1989; 170: 1231-1241.
22. Heumann D., Gallay P., Barras C. et al. Control of lipopolysaccharide (LPS) binding and LPS-induced tumor necrosis factor secretion in human peripheral blood monocytes. J Immunol 1992; 148: 3505-3512.
23. Hailman E., Lichenstein H.S., Wurfel M.M. et al. Lipopolysaccharide (LPS)-binding protein accelerates the binding of LPS to CD14. J Exp Med 1994; 179: 269-297.
24. Johnson K.J., Ward P.A., Goralnick S., Osborn M.J. Isolation from human serum of an inactivation of bacterial lipopolysaccharide. Am J Pathol 1977; 88: 559-574.
25. Ulevitch R.J., Johnston A.R. The modification of the biophysical and endotoxic properties of bacterial lipopolysaccharide by serum. J Clin Invest 1987; 62: 1313-1324.
26. Mathison J.C., Wolfson E., Ulevitch R.J. Participation of TNF in the mediation of gram-negative-bacterial LPS-induced injury in rabbits. J Clin Invest 1988; 81: 1925-1937.
27. Emancipapor K., Csako G., Elin R.J. In vitro inactivation of bacterial endotoxin by human lipoproteins and apolipoproteins. Infect Immun 1992; 60: 596-601.
28. Vukajlovich S.W. Interaction of LPS with serum complement. In: Morrison D.C., Ryan J.L. (eds) Bacterial Endotoxic Lipopolysaccharides, Vol. 2. Boca Raton, FL: CRC Press, 1992; 213-235.
29. Ohno N., Morrison D.C. Lipopolysaccharide interactions with lysozyme differentially affect lipopolysaccharide immunostimulatory activity. Eur J Biochem 1989; 186: 629-636.
30. Wollenweber H-W., Morrison D.C. Synthesis and biochemical characterization of a photoactivatable, iodinatable cleavable bacterial lipopolysaccharide derivative. J Biol Chem 1985; 260: 15068-15074.
31. Herschman H.R. Primary response genes induced by growth factors and tumor promoters. Annu Rev Biochem 1991; 60: 281-319.
32. Ray A., Tatter S.D., May L.T., Sehgal P.B. Activation of the human 'beta 2-interferon/hepatocyte-stimulating factor/IL-6' promoter by cytokines, viruses, and second messenger agonists. Proc Natl Acad Sci USA 1988; 85: 6701-6705.
33. Ray A., Corsi P.S., Sehgal P.B. A multiple cytokine- and second messenger-responsive element in the enhancer of the human interleukin-6 gene: similarities with c-fos gene regulation. Mol Cell Biol 1989; 9: 5537-5547.
34. Xie Q.W., Cho H.J., Calaycay J. et al. Cloning and characterization of inducible nitric oxide synthase from mouse macrophages. Science 1992; 256: 225-228.
35. Lyons C.R., Orloff G.J., Cunningham J.M. Molecular cloning and functional expression of an inducible nitric oxide synthase from a murine macrophage cell line. J Biol Chem 1992; 267: 6370-6374.
36. Lowenstein C.J., Glatt C.S., Bredt D.S., Snyder S.H. Cloned and expressed macrophage nitric oxide synthase contrasts with the brain enzyme. Proc Natl Acad Sci USA 1992; 89: 6711.
37. Lowenstein C.J., Alley E.W., Raval P. et al. Macrophage nitric oxide synthase gene: two upstream regions mediated induction by interferon-gamma and lipopolysaccharide. Proc Natl Acad Sci USA 1993; 90: 9730-9734.
38. Xie Q.W., Whisnant R., Nathan C. Promoter of the mouse gene encoding calcium-independent nitric oxide synthase confers inducibility by interferon-γ and bacterial lipopolysaccharide. J Exp Med 1993; 177: 1779-1784.
39. Gilbert R.S., Herschman H.R. 'Macrophage' nitric oxide synthase is a glucocorticoid-inhibitable primary response gene in 3T3 cells. J Cell Physiol 1993; 157: 128-132.
40. Zhang Y.H., Murphy W.J., Russell S.W., Morrison D.C. Macrophage activation by bacterial lipopolysaccharide (LPS): contribution of serum factors to production of nitric oxide. Abstract 9th Int Congress Immunology (San Francisco), Am Assoc Immunol and Int Union of Immunol Soc, 1995; 136.
41. Takasuka N., Matsuura K., Yamamoto S., Akagawa K.S. Suppression of TNF-alpha mRNA expression in LPS-primed macrophages occurs at the level of nuclear factor-κB activation, but not at the level of protein kinase C or CD14 expression. J Immunol 1995; 154 : 4803-4812.
42. Golenbock D.T., Hampton R.Y., Qureshi N., Takayama K., Raetz C.R. Lipid A-like molecules that antagonize the effects of endotoxins on human monocytes J Biol Chem 1991; 266: 19490-19498.
43. Manthey C.L., Vogel S.N. Taxol: a promising endotoxin research tool. J Endotoxin Res 1994; 1: 189-198.
44. Old L.J. Tumor necrosis factor. Sci Am 1988; 258: 59-60, 69-75.
45. Gifford G.E., Matthes M.L.L. Requirement for the continual presence of lipopolysaccharide for production of tumor necrosis factor by thioglycollate-induced peritoneal murine macrophages. Int J Cancer 1986; 38: 135-137.
46. Takasuka N., Matsuura K., Yamamoto S., Akagawa K.S. Suppression of TNFα mRNA expression in LPS-primed macrophages occurs at the level of nuclear factor-κB activation, but not at the level of protein kinase C or CD14 expression. J Immunol 1995; 154: 4803-4812.